Sustained transdermal delivery of zidovudine via controlled release of penetration enhancer
Seki, T; Kawaguchi, T; Juni, K; Sugibayashi, K; Morimoto, Y
| HERO ID | 1619846 |
|---|---|
| In Press | No |
| Year | 1991 |
| Title | Sustained transdermal delivery of zidovudine via controlled release of penetration enhancer |
| Authors | Seki, T; Kawaguchi, T; Juni, K; Sugibayashi, K; Morimoto, Y |
| Journal | Journal of Controlled Release |
| Volume | Controlled Release |
| Issue | REF 12 |
| Page Numbers | 1991 |
| Abstract | IPA COPYRIGHT: ASHP The effects of N-methylpyrrolidone (N-methyl-2-pyrrolidone; MP) on the permeation of zidovudine (azidothymidine; AZT) in isopropyl myristate through rat skin were studied in vitro. AZT permeation was significantly enhanced by MP. When 50 mul of solution containing 12 mg/ml zidovudine and 20% MP was applied, the plasma level of AZT was about one muM one-2 h after application, although the concentration decreased rapidly and was undetectable at 6 h. Although 34% of the applied dose remained in solution on rat skin at 10 h, MP was not detected. When ethylene-vinyl acetate copolymer (EVA) membrane was used for the controlled release of MP, a considerable plasma AZT level was maintained for 10 h. It was concluded that MP significantly enhances the permeation of AZT through rat skin, with sustained plasma levels achieved with the addition of EVA membrane. |
| Doi | 10.1016/0168-3659(91)90129-2 |
| Wosid | WOS:A1991GH35400004 |
| Is Certified Translation | No |
| Dupe Override | No |
| Comments | Authoring Organization: Dutch Expert Committee on Occupational Standards (Werkgroep van Deskundigen ter Vaststelling van MAC-waarden) |
| Is Public | Yes |
| Language Text | English |
| Keyword | <?xml version="1.0" encoding="UTF-8"?><kw>N-Methylpyrrolidone</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>effects</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>zidovudine percutaneous absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Zidovudine</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Isopropyl myristate</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>vehicles</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Ethylene-vinyl acetate copolymer</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Absorption enhancers</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Antivirals</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>zidovudine(Antivirals</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Copolymers</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>ethylene-vinyl acetate</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Blood levels</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Sustained-action medications</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Release</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>N-Methyl-2-pyrrolidone</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Azidothymidine</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>AZT</kw> |